Neil Almstead, serving as the Chief Technical Operations Officer for PTC Therapeutics, Inc. (NASDAQ: PTCT), completed a substantial divestment of equity holdings on June 22, 2026. The transaction involved the sale of 23,749 shares of common stock, yielding approximately $1.92 million. This liquidation was facilitated through the exercise of options to acquire an equivalent number of shares, all executed under a Rule 10b5-1 trading plan established by Mr. Almstead on November 11, 2025.
The timing of this sale warrants attention given the current market valuation of PTC Therapeutics. The stock was trading at $84.41 on the date of the transaction, a level close to its 52-week high of $87.50. This price point reflects a remarkable 65.5% return over the preceding twelve months. According to analysis from InvestingPro, the equity appears overvalued relative to its calculated Fair Value. Market analysts are forecasting earnings of $1.20 per share for the fiscal year 2026.
The divestment was structured across two distinct transactions. In the initial phase, Mr. Almstead sold 12,130 shares at a weighted average price of $80.61 per share. Individual trades within this segment ranged from $80.00 to $80.99. The subsequent transaction involved the sale of 11,619 shares at a weighted average price of $81.21 per share, with individual trades ranging from $81.00 to $81.57. The aggregate value of these sales reached $1,921,378, with execution prices falling between $80.61 and $81.21.
Before the liquidation, Mr. Almstead exercised options to acquire 23,749 shares at an exercise price of $25.69 per share, totaling $610,111. These options were originally granted on February 15, 2024, and are scheduled to vest over a four-year period. The vesting schedule stipulates that 25% of the options vested on February 15, 2025, with an additional 6.25% vesting every three months thereafter.
Post-transaction, Mr. Almstead's direct holdings in PTC Therapeutics common stock stand at 60,137 shares. Indirectly, through his spouse, he holds an additional 2,737 shares. Furthermore, he retains options to acquire 23,751 shares of common stock.
For investors seeking deeper insights into PTC Therapeutics' financial health and future prospects, the Pro Research Report provides comprehensive coverage as part of InvestingPro's analysis of over 1,400 US equities. The company's recent Q1 2026 performance has been characterized by strong results, surpassing analyst expectations with an earnings per share of -$0.03 against a forecast of -$0.46. Revenues reached $273 million, exceeding the anticipated $224.08 million.
In addition to these earnings results, several analyst firms have updated their positions on PTC Therapeutics. Jefferies upgraded the company's stock to a Buy rating, citing optimism about Sephience's future revenues. Similarly, TD Cowen also upgraded the stock to Buy, highlighting the company's operational improvements and successful product launches. BofA Securities reiterated its Buy rating, emphasizing the momentum of the Sephience launch and the potential for over $2 billion in global peak sales. These developments indicate a positive outlook from analysts regarding PTC Therapeutics' recent activities and future prospects.
PTC Therapeutics stock closed at $84.41, up $2.28 or 2.78%. After hours trading saw the stock at $83.03, down $1.38 or 1.63%. The stock has shown significant volatility, with a 1-day, 1-week, 1-month, 6-month, 1-year, and 5-year performance chart available for analysis. The company is included in AI-picked strategies, which evaluate PTCT alongside thousands of other companies every month using 100+ financial metrics. The AI assesses fundamentals, momentum, and valuation to identify stocks with the best risk-reward based on current data.